ESTRO 2023 - Abstract Book

S849

Digital Posters

ESTRO 2023

Just 31% of older men agreed with the statement ‘I was told everything I needed to know about sexual problems’ and only 40% described the support they received as ‘adequate’. The comparative figures for younger men were 33% and 38%. Conclusion This study is the first to report in depth on older men’s experience of sexual dysfunction associated with PCa. Findings suggest wide-ranging physical and psychological sexual side effects among men aged >75 are common and distressing. Despite this, older men are less likely to access support through HCPs. The results highlight the importance of giving older men equitable access to information and supportive care. The work forms part of an ongoing project to publish new guidelines aimed at reducing inequalities in sexual dysfunction support. V. Batumalai 1,2 , T. Twentyman 1 , M. Jameson 1,2 , J. Descallar 2 , R. Jagavkar 1 , D. Crawford 1 , M. Picton 1 , C. Tran 1 , L. McKenzie 1 , J. de Leon 1 1 GenesisCare, Radiation Oncology, Sydney, Australia; 2 School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Sydney, Australia Purpose or Objective Emerging late effects for cancer survivors requires clinicians to look ahead so that emerging treatment effects can be captured in relation to health-related quality of life (QOL). Little is known about QOL following treatment on the MR-Linac. The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) is the instrument most frequently used to assess QOL in cancer patients, and the EQ-5D-5L is widely used to measure and evaluate general health status. The primary aim of this study was to assess QOL in patients treated on the MR-linac before and after radiotherapy for a wide range of cancers. Materials and Methods Patients enrolled in the ADAPT-MRL (1) registry completed the EORTC QLQ-C30 and EQ-5D-5L questionnaires to assess QOL at baseline and 3- and 6-months after treatment on the MR-Linac. Linear regression analysis was used to assess changes in QOL scores over time. Results Among 81 patients that completed baseline and 3-month questionnaires, the median age was 68 years (range: 36-87 years), and patients were primarily male (91%). The most frequent treatment sites were prostate (47%), oligometastatic lymph nodes (30%), liver (10%) and pancreas (7%). The 6-month follow-up QOL life data was available for 52 patients. The most prominent symptoms for the EQ-5D-5L at baseline were slight pain/discomfort (30.9%) and slightly anxious/depressed (29.6%) as shown in Table 1. No statistically significant changes was noted at 3- and 6-month follow-up for any of the EQ 5D-5L questionnaires. For the EORTC QLQ-C30 questionnaires, differences of 10 or more points between baseline and follow up was interpreted as clinically meaningful. Table 2 shows that no clinically meaningful or statistically significant changes was noted after radiotherapy. PO-1062 Quality of life in patients treated with MR-Linac radiotherapy